



PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM***(to be used for all correspondence after initial filing)*

Application Number	09/998,333
Filing Date	December 3, 2001
First Named Inventor	Kathleen D. DANENBERG
Art Unit	1637
Examiner Name	Jeffrey Siew
Attorney Docket Number	11220/146

RECEIVED**OCT 31 2003****TECH CENTER 1600/2900**

Total Number of Pages in This Submission

12

ENCLOSURES (check all that apply)☒ Fee Transmittal Form☐ Fee Attached☒ Amendment / Reply☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☐ Information Disclosure Statement☐ Certified Copy of Priority Document(s)☐ Response to Missing Parts/
Incomplete Application☐ Response to Missing
Parts under 37 CFR
1.52 or 1.53☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a
Provisional Application☐ Power of Attorney, Revocation
Change of Correspondence Address☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s)☐ After Allowance Communication to
Group☐ Appeal Communication to Board of
Appeals and Interferences☐ Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s)
(please identify below):**RESPONSE TO RESTRICTION
REQUIREMENT/PRELIMINARY
AMENDMENT**

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENTFirm
or
Individual name

Teresa A. Lavenue Reg. No. 47,737

Signature

Date

October 24, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name

Signature

Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



41

1637\$

AMENDMENT TRANSMITTAL LETTER		Docket Number: 11220/146	
Application Number 09/998,333	Filing Date December 3, 2001	Examiner Jeffrey Siew	Art Unit 1637
Invention Title METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BY ASSAYING GENE EXPRESSION IN PRIMARY TUMORS		Inventors: Kathleen D. DANENBERG	

RECEIVED

Commissioner of Patents and Trademarks
PO Box 1450
Alexandria, VA 22313-1450

OCT 31 2003

TECH CENTER 1600/2900

Transmitted herewith is: (1) Amendment Transmittal, (2) Response to Restriction Requirement and (3) Preliminary Amendment

1. The filing fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT NUMBER EXTRA	RATE (\$)	FEE (\$)
TOTAL CLAIMS	19	minus	20	0	9.00	0.00
INDEPENDENT CLAIMS	5	minus	3	2	43.00	86.00
MULTIPLE DEPENDENT CLAIM ADDED					290.00	145.00
					TOTAL	86.00
If applicant is a small entity under 37 C.F.R. §§ 1.9 and 1.27, then divide total fee by 2, and enter amount here.						
SMALL ENTITY TOTAL						231.00

The Commissioner is hereby authorized to charge any extra claims fee and any underpayment or credit for overpayment to Kenyon & Kenyon's **Deposit Account No. 11-0600** for:

- Any additional filing fees required under 37 C.F.R. § 1.16.
- Any patent application processing fees under 37 C.F.R. § 1.17.

A duplicate of this sheet is attached.

Date: October 24, 2003



By: Teresa A. Lavenue
Registration No. 47,737

Kenyon & Kenyon
Suite 700, 1500 K Street, NW
Washington, DC 20005-1257
(202) 220-4200
473284



Docket No.: 11220/146

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Danenberg, Kathleen D.

Serial No.: 09/998,333

Filing Date: December 3, 2001

For: METHOD OF DETERMINING A
CHEMOTHERAPEUTIC REGIMEN BY
ASSAYING GENE EXPRESSION IN
PRIMARY TUMORS

Art Unit: 1637

Examiner: Jeffrey Siew

Customer No.: 23838

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

OCT 31 2003

TECH CENTER 1600/2900

**RESPONSE TO RESTRICTION REQUIREMENT AND
PRELIMINARY AMENDMENT**

S I R:

This is in response to the Communication from the Examiner mailed September 24, 2003 setting forth a shortened statutory response period of one month. Accordingly, this response is due on or before October 24, 2003.

The Examiner requires restriction of a single tumor gene determinant of the following invention:

- I. Claims 1-16, drawn to a method of determining a chemotherapeutic regimen using either EGFR, DPD or TS gene determinants, classified in class 435, subclass 6.

10/28/2003 TLUU11 00000008 110600 09998333

01 FC:2201
02 FC:2203

86.00 DA
145.00 DA

Applicant elects without traverse tumor gene determinant EGFR for prosecution in the present application, including claims 1-2, 5, 6, 9, 10, 13, and 16, classified in class 435, subclass 6, for prosecution in the present application. Applicant reserves the right to pursue the non-elected claims in divisional applications.

Prior to examination of the above-identified application, please make the amendment noted below:

Amendment to the Specification begins on page 3 of this paper.

Amendments to the claims begin on page 4 of this paper.

Remarks begin on page 10 of this paper.

An **Appendix** including a copy of the Declaration and Power of Attorney is attached following page 10 of this paper.